Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kura Oncology

6.45
+0.14002.22%
Volume:439.69K
Turnover:2.86M
Market Cap:520.87M
PE:-3.19
High:6.60
Open:6.47
Low:6.37
Close:6.31
Loading ...

BRIEF-Kura Oncology And Kyowa Kirin Announce Strategic Collaboration To Develop And Commercialize Ziftomenib In Acute Leukemias

Reuters
·
21 Nov 2024

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

THOMSON REUTERS
·
21 Nov 2024

Kura Oncology Inc - to Initiate Phase 3 Frontline Studies in Aml in 2025

THOMSON REUTERS
·
21 Nov 2024

Kura Oncology Inc - to Receive $330 Million Upfront, up to $1.2 Billion in Milestones

THOMSON REUTERS
·
21 Nov 2024

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

GlobeNewswire
·
21 Nov 2024

Kura Oncology: A Compelling Buy Amidst Growth Potential and Strategic Advancements

TIPRANKS
·
19 Nov 2024

Kura Oncology Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Nov 2024

Positive Outlook on Kura Oncology’s Growth Potential Amid Competitive Landscape

TIPRANKS
·
18 Nov 2024

Kura Oncology Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Nov 2024

Leerink views Syndax data as potentially positive for Kura Oncology’s ziftomenib

TIPRANKS
·
13 Nov 2024

Strong Buy Rating for Kura Oncology Based on Promising Menin Inhibitor Trials

TIPRANKS
·
13 Nov 2024

Optimistic Buy Rating for Kura Oncology: Ziftomenib’s Competitive Edge and Strong Safety Profile

TIPRANKS
·
12 Nov 2024

Stock Track | Kura Oncology Stock Plummets 5.63% Despite Clinical Progress and Strong Cash Position

Stock Track
·
09 Nov 2024

Kura Oncology Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
09 Nov 2024

Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses

GuruFocus.com
·
09 Nov 2024

Kura Oncology Positioned for Growth with Promising Trial Developments and Strong Financials

TIPRANKS
·
09 Nov 2024

Kura Oncology Receives Buy Rating: Promising Developments in NPM1m AML Treatment and Attractive Valuation

TIPRANKS
·
08 Nov 2024

Kura Oncology Q3 2024 GAAP EPS $(0.63), Inline

Benzinga
·
08 Nov 2024

Kura Oncology: Q3 Earnings Snapshot

Associated Press Finance
·
08 Nov 2024

BRIEF-Kura Oncology Q3 Operating Expenses USD 59.884 Million

Reuters
·
08 Nov 2024